March 2021 - Linnaeus

Linnaeus Therapeutics Announces Issuance of Composition of Matter Patent for LNS8801 by the U.S. Patent and Trademark Office

By wpteam|2021-03-10T14:59:51+00:00March 10th, 2021|

Linnaeus Therapeutics Announces Issuance of Composition of Matter Patent for LNS8801 by the U.S. Patent and Trademark Office US Patent 10,934,277 Issued on March 2, 2021 Haddonfield NJ, March 10, 2021-- Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage biopharmaceutical company focused on the development and [...]

Linnaeus Therapeutics Granted Orphan Drug Designation for LNS8801 for the Treatment of Patients with Metastatic Uveal Melanoma

By wpteam|2021-03-10T14:50:51+00:00March 10th, 2021|

Linnaeus Therapeutics Granted Orphan Drug Designation for LNS8801 for the Treatment of Patients with Metastatic Uveal Melanoma Haddonfield NJ, March 10, 2021--Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of novel small-molecule oncology therapeutics, today announced that the U.S. [...]